Recent Updates
Recently added Catalysts
MBX Positive Sentiment Score: 70/100

MBX Biosciences to Participate in Jefferies Healthcare Conference

Wednesday, May 24, 2023 1 min read
Key Takeaway: MBX Biosciences, a clinical stage biopharmaceutical company, has announced its participation in the upcoming Jefferies Healthcare Conference, scheduled for June 8, 2023. The company's President and CEO, Kent Hawryluk, will present and conduct one-on-one meetings with investors. This event emphasizes MBX's focus on developing Precision Endocrine Peptide therapeutics for treating endocrine disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • MBX Biosciences will present at a prominent healthcare conference.
  • The participation highlights the company's commitment to engaging with investors.
  • The focus on Precision Endocrine Peptide therapeutics showcases innovative potential.

Full Press Release Details

CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8th, 2023, at 2:30 p.m. Eastern Time and will host 1-on-1 investor meetings.
About MBX Biosciences
ian.stone@evokegroup.com
ikoffler@lifesciadvisors.com

Frequently Asked Questions

What does MBX Biosciences focus on?

MBX Biosciences develops Precision Endocrine Peptide therapeutics for endocrine disorders.

When is the Jefferies Healthcare Conference presentation?

The presentation is on June 8th, 2023, at 2:30 p.m. Eastern Time.

Who is presenting at the conference?

Kent Hawryluk, the President and CEO, will present at the conference.

Will there be investor meetings at the conference?

Yes, 1-on-1 investor meetings will be hosted by MBX Biosciences.

Tags: MBX Viatris Investor Conferences Healthcare MBX Biosciences Jefferies Healthcare Conference endocrine disorders Precision Endocrine Peptide Kent Hawryluk
Last updated: May 24, 2023